The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).
B. Moy
No relevant relationships to disclose
F. Lebrun
No relevant relationships to disclose
M. Bellet
No relevant relationships to disclose
L. Chow
No relevant relationships to disclose
I. Lang
No relevant relationships to disclose
B. Xu
No relevant relationships to disclose
R. A. Badwe
No relevant relationships to disclose
D. L. Hershman
No relevant relationships to disclose
E. Leip
Employment or Leadership Position - Pfizer
N. Bardy-Bouxin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
L. Duvillie
Employment or Leadership Position - Pfizer
P. Neven
No relevant relationships to disclose